ISSN: 2155-6156
Journal of Diabetes & Metabolism
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hypertension and Diabetes: Contribution of the Kallikrein - Kinin System

Jagdish N. Sharma* and Parvathy Narayanan
Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Centre, Kuwait University, Kuwait
Corresponding Author : Jagdish N Sharma
Department of Applied Therapeutics
Faculty of Pharmacy, Health Sciences Centre
Kuwait University, PO Box 24923
Safat 13110, Kuwait
Tel: 24986530
Fax: 24986841
E-mail: j.n.sharma@hsc.edu.kw
Received: October 17, 2011; Accepted: December 15, 2011; Published: December 19, 2011
Citation: Sharma JN, Narayanan P (2011) Hypertension and Diabetes: Contribution of the Kallikrein - Kinin System. J Diabetes Metab S4:004. doi:10.4172/2155-6156.S4-004
Copyright: © 2011 Sharma JN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Diabetes & Metabolism

Keywords
Bradykinin system; Diabetes; Hypertension; Overview
Introduction
Cardiovascular diseases are the most common cause of mortality worldwide. Hypertension and diabetes are the two major risk factors in the development of cardiac hypertrophy, ischemic heart disease and cardiac failure. Previous studies have indicated altered activities of the BK-generating components in hypertension and diabetes [1]. BK is a pharmacologically active polypeptide that can promote both cardiovascular and renal function, for example, vasodilation, natriuresis, diuresis and release of nitric oxide (NO) [2,3]. In addition, B2 kinin receptors are present in the cardiac endothelial cells which may enhance the biosynthesis and release of NO. Sharma and Uma [4] demonstrated that reduced tissue kallikrein levels may be associated with the development of high BP in spontaneously hypertensive rats (SHR) and diabetic rats. BK may produce pharmacological effects via NO and cyclic GMP (cyclic guanosine mono phosphate) release [5].
Furthermore, it has been established that kinin has cardioprotective actions in myocardial ischemia and can prevent left ventricular hypertrophy (LVH) [3]. Also, transgenic mice carrying tissue kallikrein gene and over expressing tissue kallikrein had reduced BP [6]. NO synthase and renal tissue kallikrein are both involved in BP regulation [7,8].
This update is intended to provide the readers, recent developments on the role of BK in hypertension and diabetes.
Kallikrein Kinin System (KKS)
BK is a pharmacologically active polypeptide, which is released in the tissues and body fluids as a result of enzymatic action of kallikreins on kininogens. The kinins include BK Arg-Pro-Pro-Gly-Phe-Ser-Pro- Phe-Arg), Kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and methionyl-lysyl-BK (Met-Lys-Arg-Pro-Pro-Gly-Phe-Arg). Kallidin and methionyl-lysyl-BK are converted into BK by amino peptidases present in plasma and urine. BK is rapidly (< 15 sec) inactivated by circulating kininases. Once BK is released in the blood and body fluids, it may act on two different BK receptors known as B1 and B2. The biological activities of BK per se are mediated through B2 receptor, as this receptor has a higher affinity towards these kinins. Likewise, Lys- BK preferably binds to B2 receptor. The des-Arg metabolites of these kinins (i.e. des-Arg9-BK and des-Arg10-lys_BK) have a higher affinity for the B1 receptor.
Kininogens are multifunctional proteins derived mainly from alpha- 2 globulin. In humans the two forms of kininogens are high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). These kininogens vary from each other in molecular weight, susceptibility to plasma and tissue kallikreins and in their physiological properties [1]. They are synthesized in the liver and circulate in the plasma and other body fluids.
There are two forms of kallikreins known as tissue kallikrein and plasma kallikrein. Tissue kallikrein is found in various organs such as the kidney, heart and synovial tissue. The tissue kallikrein is synthesized in the cell as a precursor and converted into the active form by the cleavage of an amino terminal peptide [9]. Active tissue kallikrein acts on LMWK to release kallidin. Tissue and plasma kallikreins differ from one another in molecular weight, biological functions, physicochemical and immunological properties. The plasma kallikrein is present in circulation in an inactive form, which is known as plasma prekallikrein or Fletcher factor. This plasma prekallikrein is converted to active plasma kallikrein by activated Hageman factor (XIIa). Also factor XIIa can liberate BK from HMWK in the absence of plasma kallikrein. In addition, plasma kallikrein is able to convert inactive factor XII to XIIa by positive feedback reaction [9]. The majority of plasma prekallikrein circulates as a non-covalent complex with HMWK. Factor XIIa and factor XI circulate with HMWK in bound form. In this way, factor XI can be converted into XIa for the participation in the intrinsic coagulation cascade. Treatment of cells or cellular matrices with HMWK and plasma prekallikrein in the absence of factor XIIa generates plasma kallikrein activity [10]. Plasma kallikrein activity is generated following treatment of cells with factor XIIa-deficient plasma, but not plasma prekallikrein-deficient plasma [11]. Activity of a partially purified plasma prekallikrein activator is not inhibited by factor XII-neutralizing antibodies and demonstrated negligible activity against factor XIIa substrates [12].
Furthermore, it is of interest to state that the tissue kallikreinkinin- system is the least complex of the two KKS as it only involves LMWK. However the plasma KKS is more complex, involving several molecules bound to the cell surface. The conversion of plasma prekallikrein into plasma kallikrein by factor XIIa only occurs ex vivo on non-physiological, negatively charged surfaces, such as glass and silica. It is now accepted that factor XII activation is not the initiating step in kallikrein-kinin activation, but instead is a secondary event which serves to increase the rate and extent of the reaction initiated by plasma kallikrein [10,11].
In immunological reactions, the tissue proteoglycan and mast cell heparin might act as an initiating surface for initial activation of the Hageman factor [13]. It seems that the kinins may be generated in parallel with the formation of thrombin at inflammatory sites, since plasma prekallikrein can be activated by coagulant Hageman factor. The tissue kallikrein multigene family comprises closely related cluster of genes that vary in number between the different mammalian species: 24 genes have been identified in the mouse, 20 in the rat, 3 in humans and 3 in the hamster [1,14].
Several restriction fragment length polymorphisms (RFLP) have been mapped in tissue kallikrein gene and their regulatory regions in SHR [15]. These findings may reflect a possible difference in the tissue kallikrein gene locus between SHR and normotensive Wistar-Kyoto (WK) rats. A tissue kallikrein RFLP has been indicated to co-segregate with high BP in the F2 offspring of SHR and normotensive Brown Norway rat crosses [14]. This finding strongly suggests a possibility of a close linkage between the kallikrein gene locus and the hypertensive phenotype of SHR.
Kininases, kinin inactivating enzymes, are present in the plasma, endothelial cells and in the tissues to regulate the physiological functions of the kinins in the body. These are known as kininase I, and kininase II [angiotensin converting enzyme (ACE)] and encephalinase. In plasma, kininase I cleaves the C-terminal argentine of BK to form des-Arg9-BK. Kininase II causes inactivation of BK by releasing pentapeptide (Arg-Pro-Pro-Gly-Phe) and tripeptide (Ser-Pro-Phe) fragments (Figure 1).
Interaction between kinins and their specific receptors can lead to activation of several second messenger systems. The BK receptor stimulation initiate the second messenger pathways, such as the arachidonic acid products and the activation of calcium sensitive systems [16]. The elevation of cellular inositol phosphates by BK involves G-protein coupled activation of phospholipase A2 and C that are used in the synthesis of eicosanoids [17]. It is of interest that indomethacin, a cyclooxygenase inhibitor, was able to cause potentiation of BK-induced contractions in guinea pig tracheal smooth muscle preparations [18]. These findings may suggest that there could be non-eicosanoid pathways for the cellular and molecular actions of BK.
Furthermore, it is known that BK significantly stimulates phosphoinositide hydrolysis in guinea pig ileum longitudinal muscle that may result in elevation of cytosolic calcium ion levels to induce contractile responses. Schini et al. [19] demonstrated that the B2 receptor stimulation causes production of cyclic GMP in cultured porcine aortic endothelial cells. The formation of cyclic GMP may be an important step for the biological actions as well as release of NO evoked by BK in the endothelial cells and in the vascular smooth muscles.
Hypertension and the Kinin System
Hypertension is a major risk factor in the development of cardiovascular diseases, such as coronary heart disease, congestive heart failure and peripheral vascular & renal diseases. There is ample evidence documenting the role of BK in the pathogenesis of hypertension [2,20]. The pharmacological actions of BK in regulation of systemic BP are vasodilation in most areas of circulation, reduction in total peripheral vascular resistance and regulation of sodium excretion from the kidney [21]. The role of KKS in hypertension was established by Margolius and co-investigators [22-23] with the observations that urinary kallikrein excretion is significantly reduced in hypertensive patients and hypertensive rats. This led to the suggestion that reduced urinary kallikrein excretion might result from a reduction in kinin generation in hypertensive situations. Research on the systemic changes in the kallikrein has provided further insight regarding the mechanisms of various hypertensive conditions. In this connection, it is known that kininogen levels and kinin-forming factors are reduced in essential and malignant hypertension [24]. It may be that a deficiency of plasma HMWK due to a decrease in liver synthesis (which decreases kinin production) occurs in an individual who develops hypertension after mild exercise [25]. It is proposed here that a deficiency in BK might be a significant factor in the pathophysiology of hypertension. In this regard, it is suggested that the role of renal BK is to excrete the excess sodium. Therefore, a reduction in the generation of renal BK may be the cause in the development of hypertension as a result of the accumulation of sodium in the body [2]. Thus, the development of a compound having renal kallikrein-like activity may serve the purpose of excreting excessive sodium from the kidney in the treatment of hypertension. Also it has been demonstrated that transgenic mice over-expressing renal tissue kallikrein were hypotensive and that administration of aprotinin, restored the BP of the transgenic mice [6]. We have shown the suppression of hypotensive responses of angiotensin converting enzyme inhibitors (ACEIs) by aprotinin in SHR [26]. These findings highlight a role of tissue kallikrein in the regulation of BP. Recently, it has been proposed that tissue kallikrein gene delivery into various hypertensive models exhibits protection, such as reduction in high BP, attenuation of cardiac hypertrophy, inhibition of renal damage and stenosis [27-30]. Furthermore, gene delivery of kallikrein binding protein re-establishes a normotensive state in tissue kallikrein overexpressing mice [31]. This may indicate the future therapeutics aspect of kallikrein gene therapy for cardiovascular and renal pathology.
ACEIs are currently used in the treatment of both clinical and experimental hypertension [32,33]. ACEIs could lower BP by inhibiting the biodegradation of kinin as well as blocking the formation of angiotensinII (AgII). A calcium-channel blocker, nifedipine, used in treatment of patients with essential hypertension can normalize the reduced urinary kallikrein excretion [34]. Smith et al. [35] have suggested that women with reduced activity of the renal BK may be at increased risk of developing pregnancy-induced hypertension. Previous study has demonstrated that urinary kallikrein excretion was found to be diminished in family members at risk for hereditary hypertension and that urinary kallikrein may be one of the major genetic markers associated with family history of hypertension [36].
LVH is regarded as an independent risk factor in hypertensive patients in inducing cardiac abnormalities. BK can counter the development of LVH in rats with hypertension produced by aortic banding [37,38]. This anti-hypertrophic effect of BK was abolished by use of a B2 receptor antagonist or inhibitor of NO formation. Thus, BK has a role in protecting the heart against developing (LVH) by releasing NO in this model of hypertension induced by aortic banding. In this regard, we have for the first time demonstrated that the lack of the cardiac KKS could be responsible for the induction of LVH in SHR and SHR with diabetes [39,40]. It is suggested that the reduced cardiac tissue kallikrein and cardiac kininogen may be responsible for reduced BK generation in the heart.
Therefore, deficient components of the BK system in the heart may be responsible for inducing excessive hypertrophy and myocardial dysfunction in cases of hypertension. It is highly desirable to develop stable compounds of BK to evaluate their efficacy and potency in cases of cardiac failure, cardiac ischemia and hypertension.
It is the generally accepted view that the BK-induced BP lowering effect is mediated by the B2 receptor, but B1 receptor might also be involved under special situations [41]. It has been demonstrated that a B2 receptor antagonist (B5630) can generally abolish the hypotensive effects of BK as well as captopril, an ACEI [42]. This led to the proposal that the hypotensive action of ACEIs might be due to the activation of B2 receptor. The accumulation of BK after treatment with ACEIs with subsequent release of NO, prostaglandins (PGs) and prostacyclin (PGI2) could account for additional mediators released in the process of anti-hypertensive action of these drugs in hypertensive patients.
Diabetes and the Kinin System
Several investigators [43-47] have reported alterations of the renal KKS in the diabetic state. Insulin- treated moderately hyperglycemic diabetic rats and patients with diabetes mellitus have been reported to show increased urinary kallikrein and BK excretion [44]. These findings suggest that alterations in the kinin-forming components may be the indicator of vascular disease in type 2 diabetics. The renal hyperfiltration in diabetic rats was reduced after pretreatment with aprotinin, suggesting a role of KKS in diabetic state of increased glomerular hemodynamics [48]. In addition, Vieira et al. [49] demonstrated the renal conversion of T-kinin (present in rats) to BK. The conversion of T-kinin, which is the main kinin in inflammation in rats, could be an important alternative pathway for the generation of renal BK in diabetic rats. On the other hand, the metabolism of BK might be impaired and it has to be shown whether changes in the activity of kininases could lead to an increased urinary BK excretion under diabetic conditions. In our earlier studies, we observed the reduction in cardiac and plasma kallikrein and kininogen concentrations in hypertensive and diabetic rats [39]. These studies suggested that the development of LVH and high BP in these diabetic rats could be the reflection of hypo- activity of the KKS. These research findings were indeed supported by the fact that the reduced synthesis of the myocardial tissue kallikrein implies a reduced capacity to generate BK in diabetic rats [45,50,51]. It can be postulated, therefore, that alterations of the KKS may contribute to the cardiac dysfunction in diabetes mellitus in human patients. Furthermore, it is suggested that treatment with KKS components in diabetic conditions may reverse the myocardial abnormalities observed in diabetic patients. Recently, it has been reported that high plasma prekallikrein activity may serve as a marker for diabetic hypertensive nephropathy [45], which may be the marker of vascular disease in diabetic patients. It has been recently pointed out that cardioprotective effects of the KKS in the diabetic heart suggest that stimulation of the KKS might open new avenues for the treatment of diabetic cardiopathy due to down regulation of kinin inactivating enzymes [10,52,53]. Also, BK2 receptor activation may contribute to the development of diabetic nephropathy [54]. On the other hand, kallikrein gene delivery improves serum glucose and lipid profile and cardiac function in experimental diabetes [55]. Recently, it has been suggested that BK system may be a therapeutic target in preventing and treating diabetic nephropathy [56].
We recently demonstrated that a decrease in tissue kallikrein and plasma kininogen activity in diabetic WK rats may be associated with the development of LVH [57]. Furthermore, treatment with captopril resulted in rise in tissue kallikrein activity as well as kininogen levels in reducing LVH in these diabetic rats (Figures 2-5).
Conclusion
Abnormal BK components might be responsible for the development of hypertension and diabetes as presented in the review. Drug development to improve the BK functions may help in the treatment of hypertension and diabetes in future. Several investigations are in the progress to establish these facts.
References
























































Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acute Pancreatitis
Disc Acute Pancreatitis Symptoms
Disc Adrenal Disorders
Disc Advanced Type 1 Diabetes Treatment
Disc Advanced Type 2 Diabetes Treatment
Disc Advances in Steroids Detection
Disc Advances in Steroids Treatment
Disc Advances of Diabetes Cure
Disc Anabolic Steroids
Disc Appetite
Disc Basal Metabolic Rate
Disc Behavioral Endocrinology
Disc Belly Fat
Disc Biliary Dyskinesia
Disc Calcium Homeostasis
Disc Catabolic Steroids
Disc Cellular Endocrinology
Disc Childhood Diabetes
Disc Childhood Obesity
Disc Chronic Pancreatitis
Disc Comparative Endocrinology
Disc Complications of Hyperglycemia
Disc Complications of Hypoglycemia
Disc Cortico Steroids
Disc Cortisol
Disc Diabetes
Disc Diabetes Cholestrol
Disc Diabetes Clinical Trials
Disc Diabetes Lipid Metabolism
Disc Diabetes Research and Clinical Practice
Disc Diabetes Statistics
Disc Diabetes and Alcohol
Disc Diabetes and Weight Loss
Disc Diabetes for Dummies
Disc Diabetic Amyotrophy
Disc Diabetic Cardiomyopathy
Disc Diabetic Nephropathy
Disc Diabetic Neuropathy
Disc Diabetic Nutrition
Disc Diabetic Peripheral Neuropathy
Disc Diabetic Retinopathy
Disc Dietary Intake
Disc Eating Disorders
Disc Endocrine Oncology
Disc Endocrine System Diseases
Disc Endocrinologist
Disc Endocrinologist Communication
Disc Endocrinology
Disc Endocrinology Case Reports
Disc Epidural Steroids
Disc Fatigue Disorders
Disc Female Steroids
Disc Food Intolerance
Disc Gall Bladder Symptoms
Disc Gallbladder Disease
Disc Gallstone Pancreatitis
Disc Gastroparesis
Disc Graves’ Disease
Disc Gyno Steroids
Disc Hereditary Pancreatitis
Disc Hormonal Disorders
Disc Hormonal Imbalance
Disc Hormonal Therapy
Disc Hormone Epinephrine
Disc Hydrocortisone
Disc Illegal Steroids
Disc Infertility
Disc Inflamed Pancreas
Disc Insulin Resistance
Disc Iodine Deficiency Disorders
Disc Latest Research on Diabetes
Disc Liquid Steroids
Disc Malnutrition
Disc Menopause
Disc Metabolic Acidosis
Disc Metabolic Disorder
Disc Metabolic Nutrition
Disc Metabolic Pathway
Disc Metabolic Syndrome
Disc Metabolic Syndrome Diet
Disc Metabolic Weight Loss
Disc Metabolism
Disc Metabolism Boosters
Disc Nasal Steroids
Disc Neuro-Endocrinology
Disc Neuroactive steroids
Disc Nutrient Deficiencies
Disc Nutrition Cancer
Disc Nutritional Epidemiology
Disc Obesity Prevention
Disc Obesity and Diabetes
Disc Oral Steroids
Disc Paediatric Endocrinology
Disc Pancreas Anatomy
Disc Pancreas Pain
Disc Pancreatectomy
Disc Pancreatic Disorder
Disc Pancreatic Duct
Disc Pancreatic Enzyme Replacement Therapy
Disc Pancreatitis
Disc Pancreatitis Symptoms
Disc Parathyroid
Disc Pathophysiology of Diabetes
Disc Proton Therapy Pancreatic Cancer
Disc Public Health Nutrition
Disc Reverse Diabetes
Disc Sex Hormone
Disc Steroid Myopathy
Disc Steroid Transformation
Disc Steroids Addiction
Disc Steroids Supplements
Disc Steroids and Alcohol
Disc Steroids in Pregnancy
Disc Swollen Pancreas
Disc Syndrome X
Disc Synthetic Steroids
Disc Type 1 Diabetes
Disc Type 2 Diabetes
Disc Veterinary Steroids
Disc Vitamin B12 Deficiency
 
Recommended Journals
Disc Clinical Diabetes Journal
Disc Pancreatic Disorders Journal
Disc Nutritional Disorders Journal
Disc Diabetic Complications Journal
Disc Metabolic Syndrome Journal
Disc Endocrinology Journal
  View More»
 
Recommended Conferences
Disc Asia-Pacific Diabetes Conference
Jul 11-13, 2016, Brisbane, Australia
Disc 12th Diabetes Meeting and Therapeutics Expo
September 29-October 1, 2016 Toronto, Canada
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11160
  [From(publication date):
specialissue-2012 - May 29, 2016]
  Breakdown by view type
  HTML page views : 7429
  PDF downloads :3731
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version